| | | High volume (N = 563) | Medium volume (N = 373) | Low volume (N = 4471) | Total (N = 5407) | value |
| | Age at diagnosis | | 0.0085 | | Mean (SD) | 59.6 (14.3) | 58.5 (14.4) | 60.7 (14.2) | 60.4 (14.2) | | | Median | 60.0 | 59.0 | 62.0 | 61.0 | | | Q1, Q3 | 51.0, 70.0 | 50.0, 68.0 | 52.0, 71.0 | 52.0, 71.0 | | | Range | (19.0–90.0) | (18.0–88.0) | (18.0–90.0) | (18.0–90.0) |
| | Sex | | 0.0001 | | Male | 304 (54.0%) | 193 (51.7%) | 2028 (45.4%) | 2525 (46.7%) | | | Female | 259 (46.0%) | 180 (48.3%) | 2443 (54.6%) | 2882 (53.3%) |
| | Race | | 0.0010 | | Black | 34 (6.0%) | 30 (8.0%) | 500 (11.2%) | 564 (10.4%) | | | Other | 29 (5.2%) | 26 (7.0%) | 271 (6.1%) | 326 (6.0%) | | White | 500 (88.8%) | 317 (85.0%) | 3700 (82.8%) | 4517 (83.5%) |
| | Charlson–Deyo score | | 0.0047 | | 0 | 472 (83.8%) | 307 (82.3%) | 3500 (78.3%) | 4279 (79.1%) | | | 1 | 79 (14.0%) | 52 (13.9%) | 755 (16.9%) | 886 (16.4%) | | 2 | 12 (2.1%) | 14 (3.8%) | 216 (4.8%) | 242 (4.5%) |
| | Year of diagnosis | | 0.37 | | 2004 | 49 (8.7%) | 20 (5.4%) | 353 (7.9%) | 422 (7.8%) | | | 2005 | 41 (7.3%) | 25 (6.7%) | 392 (8.8%) | 458 (8.5%) | | 2006 | 56 (9.9%) | 37 (9.9%) | 404 (9.0%) | 497 (9.2%) | | 2007 | 56 (9.9%) | 38 (10.2%) | 422 (9.4%) | 516 (9.5%) | | 2008 | 66 (11.7%) | 37 (9.9%) | 453 (10.1%) | 556 (10.3%) | | 2009 | 64 (11.4%) | 34 (9.1%) | 452 (10.1%) | 550 (10.2%) | | 2010 | 51 (9.1%) | 38 (10.2%) | 479 (10.7%) | 568 (10.5%) | | 2011 | 68 (12.1%) | 48 (12.9%) | 522 (11.7%) | 638 (11.8%) | | 2012 | 59 (10.5%) | 59 (15.8%) | 508 (11.4%) | 626 (11.6%) | | 2013 | 53 (9.4%) | 37 (9.9%) | 486 (10.9%) | 576 (10.7%) |
| | Facility type | | <0.0001 | | Missing | 48 | 39 | 364 | 451 | | | Community cancer program | 0 (0.0%) | 1 (0.3%) | 230 (5.6%) | 231 (4.7%) | | Comprehensive community cancer program | 0 (0.0%) | 0 (0.0%) | 1428 (34.8%) | 1428 (28.8%) | | Academic/research program | 515 (100.0%) | 283 (84.7%) | 2023 (49.3%) | 2821 (56.9%) | | Integrated network cancer program | 0 (0.0%) | 50 (15.0%) | 426 (10.4%) | 476 (9.6%) |
| | Primary payor | | <0.0001 | | Not insured | 7 (1.2%) | 10 (2.7%) | 181 (4.0%) | 198 (3.7%) | | | Private insurance | 243 (43.2%) | 195 (52.3%) | 2127 (47.6%) | 2565 (47.4%) | | Medicaid | 17 (3.0%) | 25 (6.7%) | 271 (6.1%) | 313 (5.8%) | | Medicare | 168 (29.8%) | 131 (35.1%) | 1774 (39.7%) | 2073 (38.3%) | | Other government | 5 (0.9%) | 1 (0.3%) | 61 (1.4%) | 67 (1.2%) | | Insurance status unknown | 123 (21.8%) | 11 (2.9%) | 57 (1.3%) | 191 (3.5%) |
| | Median income quartiles | | 0.0078 | | Missing | 36 | 10 | 159 | 205 | | | <$30,000 | 36 (6.8%) | 41 (11.3%) | 547 (12.7%) | 624 (12.0%) | | $30,000–$35,999 | 98 (18.6%) | 67 (18.5%) | 716 (16.6%) | 881 (16.9%) | | $36,000–$45,999 | 139 (26.4%) | 101 (27.8%) | 1124 (26.1%) | 1364 (26.2%) | | $46,000+ | 254 (48.2%) | 154 (42.4%) | 1925 (44.6%) | 2333 (44.8%) |
| | No high school degree (%) | | <0.0001 | | Missing | 36 | 10 | 159 | 205 | | | ≥29% | 58 (11.0%) | 33 (9.1%) | 681 (15.8%) | 772 (14.8%) | | 20–28.9% | 96 (18.2%) | 91 (25.1%) | 961 (22.3%) | 1148 (22.1%) | | 14–19.9% | 125 (23.7%) | 96 (26.4%) | 994 (23.1%) | 1215 (23.4%) | | <14% | 248 (47.1%) | 143 (39.4%) | 1676 (38.9%) | 2067 (39.7%) |
| | Distance to treating center (miles) | | <0.0001 | | Mean (SD) | 223.5 (389.7) | 68.2 (119.1) | 39.5 (136.1) | 60.6 (187.7) | | | Median | 75.9 | 38.4 | 12.4 | 15.4 | | Q1, Q3 | 22.4, 242.7 | 15.0, 89.8 | 5.1, 33.5 | 5.8, 46.2 | | Range | (1.0–4040.1) | (1.0–1495.6) | (1.0–4710.1) | (1.0–4710.1) |
| | Histologic subtype | | <0.0001 | | Dedifferentiated liposarcoma | 160 (28.4%) | 81 (21.7%) | 755 (16.9%) | 996 (18.4%) | | | Fibrosarcoma | 10 (1.8%) | 5 (1.3%) | 67 (1.5%) | 82 (1.5%) | | Leiomyosarcoma | 98 (17.4%) | 88 (23.6%) | 1069 (23.9%) | 1255 (23.2%) | | Liposarcoma | 188 (33.4%) | 98 (26.3%) | 1468 (32.8%) | 1754 (32.4%) | | MFH | 5 (0.9%) | 5 (1.3%) | 96 (2.1%) | 106 (2.0%) | | MPNST | 6 (1.1%) | 6 (1.6%) | 42 (0.9%) | 54 (1.0%) | | Rare/NOS | 96 (17.1%) | 90 (24.1%) | 974 (21.8%) | 1160 (21.5%) |
| | Grade | | <0.0001 | | Missing | 97 | 71 | 992 | 1160 | | | Well differentiated | 172 (36.9%) | 85 (28.1%) | 1256 (36.1%) | 1513 (35.6%) | | Mod differentiated | 23 (4.9%) | 38 (12.6%) | 587 (16.9%) | 648 (15.3%) | | Poorly differentiated | 99 (21.2%) | 111 (36.8%) | 1019 (29.3%) | 1229 (28.9%) | | Undifferentiated | 172 (36.9%) | 68 (22.5%) | 617 (17.7%) | 857 (20.2%) |
| | Tumor size | | 0.35 | | Missing | 36 | 17 | 327 | 380 | | | 5–10 cm | 98 (18.6%) | 80 (22.5%) | 848 (20.5%) | 1026 (20.4%) | | <5 cm | 42 (8.0%) | 27 (7.6%) | 391 (9.4%) | 460 (9.2%) | | >10 cm | 387 (73.4%) | 249 (69.9%) | 2905 (70.1%) | 3541 (70.4%) |
| | AJCC stage group | | <0.0001 | | Stage I | 180 (32.0%) | 90 (24.1%) | 1322 (29.6%) | 1592 (29.4%) | | | Stage II | 49 (8.7%) | 39 (10.5%) | 560 (12.5%) | 648 (12.0%) | | Stage III | 204 (36.2%) | 140 (37.5%) | 1278 (28.6%) | 1622 (30.0%) | | Stage IV | 38 (6.7%) | 20 (5.4%) | 314 (7.0%) | 372 (6.9%) | | AJCC staging not applicable | 22 (3.9%) | 27 (7.2%) | 275 (6.2%) | 324 (6.0%) | | AJCC stage group unknown | 70 (12.4%) | 57 (15.3%) | 722 (16.1%) | 849 (15.7%) |
| | Surgery | | <0.0001 | | No | 53 (9.4%) | 73 (19.6%) | 1198 (26.8%) | 1324 (24.5%) | | | Yes | 510 (90.6%) | 300 (80.4%) | 3273 (73.2%) | 4083 (75.5%) |
| | Radiation | | <0.0001 | | Missing | 0 | 1 | 79 | 80 | | | No | 453 (80.5%) | 293 (78.8%) | 3196 (72.8%) | 3942 (74.0%) | | Yes | 110 (19.5%) | 79 (21.2%) | 1196 (27.2%) | 1385 (26.0%) |
| | Chemotherapy | | 0.0001 | | Missing | 6 | 11 | 188 | 205 | | | No | 469 (84.2%) | 270 (74.6%) | 3569 (83.3%) | 4308 (82.8%) | | Yes | 88 (15.8%) | 92 (25.4%) | 714 (16.7%) | 894 (17.2%) |
| | Last contact or death, months from Dx | | 0.68 | | Mean (SD) | 41.7 (27.4) | 42.3 (31.6) | 43.8 (32.2) | 43.5 (31.7) | | | Median | 37.6 | 35.8 | 37.2 | 37.1 | | | Q1, Q3 | 20.0, 58.0 | 16.8, 61.0 | 17.9, 64.8 | 18.1, 63.5 | | | Range | (0.6–133.1) | (1.2–132.5) | (0.0–142.6) | (0.0–142.6) |
| | Vital status | | <0.0001 | | Dead | 177 (31.4%) | 151 (40.5%) | 1954 (43.7%) | 2282 (42.2%) | | | Alive | 386 (68.6%) | 222 (59.5%) | 2517 (56.3%) | 3125 (57.8%) |
| | Hospital volume | | <0.0001 | | Mean (SD) | 153.7 (46.5) | 62.6 (5.0) | 14.4 (12.5) | 32.2 (47.1) | | | Median | 134.0 | 64.0 | 10.0 | 13.0 | | | Q1, Q3 | 114.0, 212.0 | 62.0, 65.0 | 5.0, 22.0 | 6.0, 35.0 | | | Range | (103.0–212.0) | (51.0–68.0) | (1.0–47.0) | (1.0–212.0) | |
|
|
